DRVVT confirmation (1:1 mix), preliminary

This test is a preliminary confirmation step within the dilute Russell viper venom time (DRVVT) evaluation for lupus anticoagulant. It measures how your plasma clots when triggered by a venom-derived reagent after it has been mixed in equal parts with normal plasma. The mixing step helps sort out whether an abnormal clotting result is due to an inhibitor in the blood or a deficiency of a clotting factor.

Because it is a preliminary confirmation measurement, it is interpreted together with the DRVVT screen, a full confirmation step that uses excess phospholipid, and related antiphospholipid antibody tests. On its own it does not diagnose a condition, but it supports the assessment for antiphospholipid antibodies in the right clinical setting.

Lupus anticoagulant is an autoantibody that can interfere with laboratory clotting assays and is linked to a higher risk of blood clots and certain pregnancy complications. Your clinician may order this test if you have an unexplained clot, a prolonged clotting time, recurrent pregnancy loss, or other findings that raise concern for antiphospholipid syndrome.

The 1:1 confirmation result helps clarify whether an abnormal screening result persists after mixing, which supports an inhibitor such as lupus anticoagulant, or corrects toward normal, which points to a clotting factor deficiency or another influence. This distinction guides further testing and helps inform decisions about monitoring and treatment.

Results are interpreted as part of a panel rather than in isolation. If the preliminary confirmation remains abnormal compared with expectations after mixing with normal plasma, it suggests a persistent inhibitor effect that can be seen with lupus anticoagulant. If the result improves after mixing, a factor deficiency or medication effect is more likely.

Medicines and health conditions can influence this assay, so your clinician will review the findings together with your history, medication list, and related tests such as anticardiolipin and anti beta-2 glycoprotein I antibodies. If results are borderline or do not fit your clinical picture, your care team may repeat testing at a later time or use strategies to reduce drug interference before making long term decisions.